PONVORY™ (ponesimod tablets)

PREGNANCY REMINDER CARD

Information for female patients of childbearing potential

BEFORE STARTING PONVORY™

- PONVORY™ is used to treat adults with relapsing remitting Multiple Sclerosis (RRMS).
- PONVORY™ must not be used during pregnancy or by women of childbearing potential not using highly
 effective contraception. PONVORY™ may harm your unborn baby.
- Your doctor should perform a pregnancy test to confirm that you are not pregnant before you start treatment with PONVORY™.
- Do not use PONVORY™ if you are of childbearing age and not using an effective method of birth control.
 Women of childbearing potential should be counseled on the potential for a serious risk to the fetus and the need for highly effective contraception during treatment with PONVORY™.
- You should not use PONVORY™ if you are pregnant, think you may be pregnant or plan to get pregnant.
- If you are breastfeeding or planning to breast-feed your baby, inform your doctor and discuss continuing your treatment or other treatment options as PONVORY™ as a risk to newborns/infants cannot be excluded.
- Consult your doctor about effective contraception you should use throughout therapy and for at least 2 weeks after stopping PONVORY® medication.

This risk minimization activity has been reviewed and approved by the Saudi FDA Version 2, 10/2024

DURING TREATMENT WITH PONVORYTM

- You must not become pregnant while taking PONVORY™. A pregnancy test should be repeated
 at suitable times during PONVORY® treatment.
- If you become pregnant while taking PONVORY™, stop taking it and tell your doctor right away.

 PONVORY™ may harm your unborn baby.
- If you are of childbearing potential, and you might get pregnant, you should use effective birth control
 methods during treatment and for at least 1 week after stopping PONVORY™. Ask your doctor about
 options of effective birth control.
- If you suspect pregnancy or decide to become pregnant, you should tell your doctor straight away.
- You should not breastfeed while taking PONVORY®.

This risk minimization activity has been reviewed and approved by the Saudi FDA Version 2, 10/2024

AFTER STOPPING PONVORYTM TREATMENT

- You must not become pregnant for at least 1 week after you stop taking PONVORY™. If you become pregnant while taking PONVORY™, stop taking it and tell your doctor right away. PONVORY™ may harm your unborn baby.
- If you stop taking PONVORY® because you are pregnant or trying to get pregnant, your
 multiple sclerosis symptoms may come back, grow worse, or develop new symptoms.
 If you feel this after stopping your PONVORY® treatment, consult your doctor right away.



Adverse events reporting guidance:

FDA (National Pharmacovigilance center) Email: npc.drug@sfda.gov.sa

Telephone: 19999 Online: http://ade.sfda.gov.sa

For full prescribing information, please refer to the datasheet or contact

Johnson & Johnson Middle East FZ-LLC (Riyadh) Address: Prince Muhammed Bin Abdulaziz Rd. Tower B. Level 30. Olava towers.

Postal address: P O Box 65305 Riyadh 11556, Saudi Arabia

Office Tel 00966-11-4339133

To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at: Email: GCC-PV2@its.jnj.com

Email: GCC-PV2@its.jnj.com Hotline: 00966540015811



